The AudioNotch Tinnitus Treatment Blog

We’ve posted about another drug called AM-101 that acts in the same fashion, and here’s a new one:

Ear disease-focused firm Otonomy has entered an agreement with Ipsenallowing Otonomy to use Ipsen’s gacyclidine data in the development and registration of OTO-311, Otonomy’s sustained-exposure formulation of gacyclidine in development for the treatment of tinnitus. Gacyclidine is an N-Methyl-D-Aspartate (NMDA) receptor antagonist; according to Otonomy, clinical studies show NMDA receptor antagonists could be used to treat the ear disorder.